US 9388221
Papillomavirus L2 N-terminal peptides for the induction of broadly cross-neutralizing antibodies
granted A61KA61K2039/5258A61K2039/53
Quick answer
US patent 9388221 (Papillomavirus L2 N-terminal peptides for the induction of broadly cross-neutralizing antibodies) held by The United States of America as Represented by the Secretary, Dept. of Health and Human Services expires Mon Jul 07 2036 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- The United States of America as Represented by the Secretary, Dept. of Health and Human Services
- Grant date
- Tue Jul 12 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jul 07 2036 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 5
- CPC classes
- A61K, A61K2039/5258, A61K2039/53, A61K2039/55566, A61K2039/58